HOZ Medical closes Series B round, raises nearly RMB100m

The neurosurgery robot research and development company HOZ Medical has raised nearly 100 million yuan in Series B financing round. Since its inception, the company has completed three rounds of financing. Prior to this, it has completed the 50 million yuan financing round led by Tasly Holdings Group and Series A round of tens of millions of yuan led by Tongsheng Capital.

The neurosurgery robot research and development company HOZ Medical has raised nearly 100 million yuan in Series B financing round. Since its inception, the company has completed three rounds of financing. Prior to this, it has completed the 50 million yuan financing round led by Tasly Holdings Group and Series A round of tens of millions of yuan led by Tongsheng Capital.

Founded in 2000, HOZ Medical is the earliest Chinese enterprise engaged in the research and development, and production of neurosurgery robots. Upon the completion of its Series B round of financing, the company will continue to develop markets for certified products, and concentrate on research and development, upgrade technology innovation platforms, and accelerate the development of other product lines.

The core product of HOZ Medical, neurosurgery navigation positioning surgical robot “CAS-R-2 frameless stereotactic brain surgical system” has been utilized in nearly 100,000 surgical cases with no adverse reports to date. It is the minimally invasive surgical robot with the most clinical cases in China.

As of 2019, CAS-R-2 has been deployed in more than 100 hospitals in China including Huashan Hospital of Fudan University, Xuanwu Hospital, Chinese PLA General Hospital, Beijing Puhua International Hospital, and The First Affiliated Hospital of Zhengzhou University.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/05/04/hoz-medical-closes-series-b-round-raises-nearly-rmb100m/.

Leave a Reply

Please Login to Comment